Retinitis pigmentosa (RP) refers to a group of inherited diseases causing retinal degeneration and a loss of peripheral and night vision over time.
The vision loss is caused by a degeneration of the rod and cone cells in the retina resulting in a loss of peripheral and night vision that becomes more constricted over time, potentially resulting in total blindness in severe cases of RP. Dozens of different genetic mutations have been linked to RP.
![Illustration of a healthy retina showing light entering and traveling through the first two layers of the retina, getting absorbed by the third, and converted into a visual signal.](/_astro/DiseaseExample1.B3u8I35J_1z2unl.png)
![Illustration of a diseased retina showing light entering and traveling through the first two layers of the retina, and not producing any further signal.](/_astro/DiseaseExample2A.DX2dI2_q_Vkmk1.png)
![Illustration showing the action of the PRIMA implant as it stimulates remaining intact neurons.](/_astro/prima-implant.CurNYOiZ_1HDCpd.png)
Our Approach to Treatment
The PRIMA implant builds on decades of research to miniaturize solar technology. It is inserted into the subretinal space where the photoreceptors have degenerated, and electrical stimulation activates the remaining intact neurons to restore vision.
Learn more about PRIMACurrent Status
While Science Corporation has not yet performed clinical studies with RP patients, in the future, Science's PRIMA device could help with central vision loss in very late stage RP and our optogenetic gene therapy could help with peripheral vision restoration.
Resources
More information about treatment options, disease details, and current research